Healius Limited (ASX:HLS)

ALERT: Price-sensitive ASX Announcement for HLS

Current share price for HLS : $0.375 -0.11 (-22.68%)⁺

Announcement

FY26 trading update and strategic review of assets

Release

13 May 2026 8:17AM

Price at Release

$0.485

Full Release

Summary

Healius Limited announced a trading update for FY26, projecting an underlying EBITDA between $259.0m and $264.0m and an EBIT between $30.0m and $35.0m. Pathology volumes saw a slight growth in revenue despite a decline in volumes, and labour costs are expected to rise due to Fair Work Commission findings on gender-based undervaluation. Additionally, Agilex Biolabs reported strong trading and is under strategic review for potential sale to optimize shareholder value, with UBS Securities assisting in the exploration. The Federal Budget posed challenges with no new funding for pathology, and the company anticipates implementing out-of-pocket fees for tests to manage the financial shortfall.

Key Points

FY26 EBITDA expected between $259.0m and $264.0m.
EBIT expected between $30.0m and $35.0m.
Pathology revenue grew despite declining volumes.
Labour costs impacted by gender undervaluation adjustments.
Agilex Biolabs revenue increased by 13.7%.
Potential sale of Agilex Biolabs under review.
No new Federal Budget funding for pathology.
Possible implementation of out-of-pocket fees for tests.

IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.